BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.26 USD | -5.68% |
|
-8.08% | -21.90% |
| May. 07 | Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
| May. 07 | Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 50.11M | Sales 2025 * | 52.04M | Capitalization | 1.68B |
|---|---|---|---|---|---|
| Net income 2024 * | -402M | Net income 2025 * | -432M | EV / Sales 2024 * | 17.8 x |
| Net cash position 2024 * | 786M | Net cash position 2025 * | 376M | EV / Sales 2025 * | 25 x |
| P/E ratio 2024 * |
-4.5
x | P/E ratio 2025 * |
-4.5
x | Employees | 346 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Beam Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | -5.68% | ||
| 1 week | -8.08% | ||
| Current month | +0.19% | ||
| 1 month | -22.04% | ||
| 3 months | -26.82% | ||
| 6 months | -4.06% | ||
| Current year | -21.90% |
1 week
21.18
23.71
1 month
20.8426.42
Current year
20.8449.50
1 year
16.9549.50
3 years
16.95138.52
5 years
13.00138.52
10 years
13.00138.52
| Managers | Title | Age | Since |
|---|---|---|---|
John Evans
CEO | Chief Executive Officer | 46 | 16-12-31 |
| President | 55 | 18-01-31 | |
| Director of Finance/CFO | 47 | 19-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Graham Cooper
BRD | Director/Board Member | 54 | 19-10-09 |
John Maraganore
BRD | Director/Board Member | 60 | 21-11-04 |
Mark Fishman
BRD | Director/Board Member | 73 | 18-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.03% | 2 M€ | -25.75% | ||
| 4.10% | 0 M€ | 0.00% | - | |
| 4.00% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 21.26 | -5.68% | 1,366,593 |
| 24-05-09 | 22.54 | +1.35% | 1,185,555 |
| 24-05-08 | 22.24 | -1.29% | 1,020,211 |
| 24-05-07 | 22.53 | -1.10% | 1,287,476 |
| 24-05-06 | 22.78 | -1.51% | 926,235 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
21.26
USD
Average target price
48.38
USD
Spread / Average Target
+127.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.90% | 1.68B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- BEAM Stock